Moreover, the sensitivity of glycoprotein biomarker assays may be enhanced by targeting the many repeated glycan epitopes, such as Neu5Gc capped glycans on cancer-derived glycoconjugates, using lectins (and IgM antibodies) for high affinity and avidity binding detection. This evidence concerns the gene CD40LG and cancer.